White Papers
As an industry, life sciences is now looking towards technological change to leverage investments made during the past few years.
In fact, according to Trinity’s TGaS Advisors, the proportion of surveyed companies reporting that they have completed proof of concept or are using GenAI at an enterprise level for commercial, medical, or customer operations surged from less than 10% in August 2023 to approximately 35% in August 2024, while those reporting no use cases for GenAI declined from 47% to…
Read Now
Blog
Published May 15, 2025
Data is the great enabler. It is the backbone of modern Customer Relationship Management (CRM) systems. Data enables businesses to understand their customers better, personalize interactions and make informed decisions. Companies that can harness the power of data have a competitive advantage now, but soon it will become a competitive disadvantage if they are unable to use this data.
“All too often we find that our clients struggle to access and organize their many sources of data into a comprehensive…
Read Now
Blog
Published May 8, 2025
The transformative potential of generative AI (GenAI) within the life sciences industry is highlighted in Everest Group’s report, “AI-deas to Action: Operationalizing Generative AI in Life Sciences.”
Fifteen companies were selected for inclusion across three categories:
Broad-based IT/Business Process Organizations (BPOs)
Clinical Research Organizations (CROs)
Life Sciences Specialists
To be included in the report, providers had to have been profiled in past Everest Group PEAK Matrix® assessments with a Harvey score of above five in Innovation and Investment, as…
Read Now
Blog
Published April 29, 2025
The first 100 days of President Trump’s return to the White House have been anything but ordinary. With a true “Flood the Zone” strategy, there has been a flurry of executive orders, leadership reshuffles, and a re-assertion of executive power, which has signaled the administration is interested in seeing what policy options can “stick.” While campaign rhetoric once suggested bold de-regulation with the potential for an industry-friendly reset, the governing reality has been less coherent and opens multiple fronts for…
Read Now
Webinars
May 21, 2025 | 1:00 - 1:45 PM ET
Two additional sessions will be offered: May 22 – 12:00 – 12:45 (UTC +8:00) – Asia/Shanghai May 22 – 12:00 – 12:45 CET – Europe/Berlin
What key insights emerged from the 2024 China National Reimbursement Drug List (NRDL) negotiations and how can they inform strategic go-to-market planning for innovative therapies?
In the 2024 NRDL negotiations, only 28% of submitted products passed expert review, significantly raising the bar for entering pricing negotiations. However, products with robust clinical differentiation or superiority can…
Sign Up Now
Blog
Published April 22, 2025
The transition to a new CRM system is more than just a technical migration; it’s a strategic choice that requires careful consideration and a strong point of view on what your organization needs for success.
To navigate the CRM transition necessitated by the Salesforce-Veeva split, it’s crucial to generate buy-in from account and field teams to ensure alignment and CRM utilization during and after the transition.
Interested in learning more about the Salesforce-Veeva split?
Read our first blog here.
Strategies…
Read Now
White Papers
Can artificial intelligence and machine learning (AIML) be used to support portfolio decision-making across the life sciences industry?
In this installment of our Industry Impact Series, we find that not only can the latest AIML techniques identify the drivers of success and failure in commercialization, but Trinity Life Sciences’ AI algorithm accurately predicts revenue outcomes for >90% of U.S. drug launches, far exceeding the accuracy of Wall Street analyst consensus at the time of launch (<60%).
Trinity’s AI algorithm incorporates publicly…
Read Now
Webinars
Available On Demand
Join Value, Access and Pricing experts Max Hunt, Mary Fletcher-Louis and Pinar Bilir as they delve into the emerging role of health equity considerations as a differentiator in value narratives for global HTA (Health Technology Assessment) submissions. NICE’s proposed methods update focused on manufacturer-submitted evidence on health inequalities.This session will explore how HTA agencies are beginning to include health equity in their access recommendations and discuss the practical impact of this trend. Our experts will share insights from Trinity Life…
Watch Now
Blog
Published April 8, 2025
A Massive Change in Customer Relationship Management (CRM) Software
The split between Veeva and Salesforce marks a significant shift in the CRM landscape.
Veeva is removing its CRM from the Salesforce cloud in September 2025 to focus on its “Veeva Vault” cloud solution for CRM. Veeva has communicated that it will maintain the current CRM product until September 2030 but will not be making any updates—and that it will absorb the cost of migration to the new Vault platform for…
Read Now
Analyst Reports
Everest Group report:
AI-deas to Action: Operationalizing Generative AI in Life Sciences
This research report provides a comprehensive analysis of how generative AI (GenAI) is being operationalized in the life sciences industry and assesses the capabilities of the fifteen vendors included.
The report highlights several of Trinity’s key strengths, including:
Life Sciences Industry Expertise
Trinity has nearly 30 years of experience in the industry, providing evidence-based solutions to over 300 clients, including the global top 20 biopharma companies. This deep…
Read Now
